What type of study is this?

This is a In Vitro Study study (also classified as: Observational).

September 5, 2025Open Access

Supplementary Figure S8 from RORγt Inhibition Reduces Protumor Inflammation and Decreases Tumor Growth in Experimental Models of Lung Cancer

View Full Paper

Ask AI

Bookmark

Authors

Inhibition of Th17 cell differentiation by RORγt inhibitors digoxin and SR2211 reduces tumor growth in lung cancer.

RORγt inhibitors significantly reduce tumor growth in experimental lung cancer models, indicating a potential therapeutic effect.
In vitro analysis shows that digoxin and SR2211 inhibit Th17 cell differentiation, which is linked to inflammation and tumor progression.
The study utilizes experimental models to assess the impact of RORγt inhibition on tumor dynamics, emphasizing inflammation's role.
Findings may suggest new avenues for lung cancer treatment through the modulation of Th17 cell activity and tumor growth.

Yamada‐Hara et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark